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CERK  ceramide kinase 
Ct threshold cycle 
DEPC diethylpyrocarbonate 
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EDTA ethylenediaminetetraacetic acid 
ERK extracellular signal–regulated kinases 
FBS fetal bovine serum 
GAPDH glyceraldehyde-3-phoshate dehydrogenase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IAP Inhibitors of apoptosis proteins 
IHC inner hair cell 
kDa kilodalton 
mRNA messenger RNA 
3 
 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
OHC outer hair cell 
P3 – P5 postnatal day 3 – postnatal day 5 
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Chapter 1. General overview  
1.1. Structures related to hearing function 
Understanding of the anatomy and physiology of cochlea is a better way to learn about 
mechanisms involved in ototoxicity and to develop a better prevention. For the purpose 
of our studies, we describe some vital structures of cochlea relating to hearing functions 
in this chapter. They include cochlear hair cells and the lateral wall (Fig. 1.1). Cochlear 
hair cells lie along the turns of the cochlea on basilar membrane. There are two types of 
cochlear hair cells: inner hair cells (IHCs) and outer hair cells (OHCs) housed in the organ 
of Corti. The inner hair cells are responsible for transferring the fluid motion into neural 
signal that can be passed to the brain. The OHCs are responsible for modifying the 
incoming signal. The lateral wall houses structures which are important in the production 
of the endocochlear potential. The endocochlear potential is a standing potential that 
exists between the endolymphatic space and the perilymphatic space. Spiral ligament 
fibrocytes of lateral wall is responsible for active accumulation of potassium ions (K+) in 
the endolymphatic space (v. Békésy 1952). The endocochlear potential and high 
endolymphatic K+ are important for K+ entry and triggering of an action potential in 
cochlear hair cells when ion channels in these cells are opened. The influx of K+ ions 
ends in changes in cell shape and then release of synaptic vesicles into the synaptic cleft 
at the base of cochlear hair cell. Although mentioned structures are essential in hearing 
function, they are very sensitive to harmful stimuli (such as loud sounds, aminoglycosides, 
or chemotherapy …), and their damages result in hearing loss. In our research, we focus 
on cisplatin-induced ototoxicity for the purpose of better understating in otoprotection. 
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 Figure 1.1: Organ of Corti housing of OHC and IHC and lateral wall housing of spiral 
ligament (SL) and stria vascularis (St) 
 
1.2. Cisplatin and ototoxicity 
Cisplatin is an effective anti-neoplastic drug for the treatment of solid tumors (Boulikas 
and Vougiouka 2004), and is the central component of several curative approaches for 
patients with head and neck cancer (Lamont and Vokes 2001). However, of all the drugs 
used in the modern chemotherapy of cancer, cisplatin occupies a unique role in causing 
significant ototoxicity in a large percentage of patients treated. Importantly, once the 
incident happens, most investigators have reported virtually no recovery in the ototoxic 
hearing loss following cessation of cisplatin treatment. Thus, cisplatin ototoxicity is 
regarded as permanent, and is linked to the degeneration of cochlear OHCs, components 
of the later wall, as well as spiral ganglion cells (Rybak, Whitworth et al. 2007). Recent 
experiment research showed that strategies for prevention of cisplatin ototoxicity could 
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be achieved by either reduction of free radical formation or manipulation of signal 
transduction pathway to increase survival and decrease apoptosis pathways (Tabuchi, 
Nishimura et al. 2011). Based on those fundamental knowledge, our research were 
conducted and results were presented in next chapters to shed more light on cisplatin 
ototoxicity and its protectors. 
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Chapter 2. Ceramide-1-phosphate protection of cochlear 
hair cells against cisplatin ototoxicity  
2.1. Introduction 
Ceramide, composing of sphingosine and a fatty acid, plays a central role in 
sphingolipid biosynthesis and catabolism. Ceramide is generally formed either via de 
novo synthesis from serine and palmitoyl-CoA involving the action of the enzymes serine 
palmitoyltransferase and ceramide synthetase, or via hydrolysis of sphingomyeline at the 
plasma membrane by sphingomyelinase (Brown and London 1998, Kolesnick, Goni et al. 
2000) (Fig. 2.1). As a bioactive lipid, ceramide has been implicated in a variety of 
physiological or pathophysilogical functions including apoptosis and cell growth arrest, 
differentiation, senescence, migration, and adhesion (Hannun and Obeid 2008). To 
achieve this, ceramides modulate diverse signal transduction pathways by activating or 
inhibiting key regulatory enzymes including protein phosphatases (Dobrowsky and 
Hannun 1992), phospholipase D (Gomez-Munoz, Martin et al. 1994), protein kinase C 
(Berra, Diaz-Meco et al. 1995), specific serine/threonine kinases (Kolesnick and Fuks 
1995), stress-activated protein kinases also known as Jun nuclear kinases (Verheij, Bose 
et al. 1996), mitogen-activated protein kinases (Spiegel, Foster et al. 1996), 
phospholipase A2 (Hayakawa, Jayadev et al. 1996), and protein kinase B (Bourbon, 
Sandirasegarane et al. 2002). Roles for ceramide as a cell-death-inducing factor have 
also been suggested in a number of pathological conditions including cancer, 
neurodegeneration, diabetes, microbial pathogenesis, obesity, and inflammation (Wu, 
Ren et al. 2007, Zeidan and Hannun 2007).  
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 Figure 2.1: bioactive sphingolipid metabolites (Chalfant and Spiegel 2005) 
 (SPP-1: S1P phosphatase-1; SphK: sphingosine kinase; S1P: sphingosine 1-
phosphate; LPP: lipid phosphate phosphatase; CERK: ceramide kinase; C1P: ceramide 
– 1- phosphate; SM: sphingomyelin) 
 
In the sphingomyelin cycle, a number of extracellular agents and insults (such as 
tumor necrosis factor, Fas ligands, and chemotherapeutic agents) cause the activation of 
sphingomyelinases, which acts on membrane sphingomyelin and releases ceramide. In 
the relation to cisplatin-induced apoptosis of cochlear hair cells, increase of ceramide was 
identified as one of decisive factors. It was demonstrated that cisplatin activates 
sphingomyelinase, which triggers the release of ceramide (Lacour, Hammann et al. 2004). 
Consequently, ceramide sensitizes cells to apoptosis by transforming cellular-membrane 
properties (Veiga, Arrondo et al. 1999, Megha and London 2004), blocking phosphatidyl-
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inositol-3-kinase (PI3-K) (Zundel, Swiersz et al. 2000), and inducing death receptors to 
transmit strong signals (Carpinteiro, Dumitru et al. 2008). Although ceramide is known to 
be an inducer of apoptosis in aminoglycoside ototoxicity (Nishimura, Tabuchi et al. 2010), 
the effects of ceramides on cisplatin ototoxicity have never been examined before.  
Ceramide-1-phosphate (C1P) is synthesized by phosphorylation of ceramide in 
mammalian cells (Dressler and Kolesnick 1990), and currently, ceramide kinase (CERK) 
is the only known mammalian enzyme to have this function. It was firstly found in human 
leukemia cells (HL-60). Later, researchers observed that endogenous C1P can be 
generated during the phagocytosis of antibody-coated erythrocytes in human neutrophils 
(Hinkovska-Galcheva, Boxer et al. 1998). Also, C1P can also be generated by the action 
of interleukin 1-β on A549 lung carcinoma cells (Pettus, Bielawska et al. 2003). More 
recently, C1P was found presented in normal bone marrow-derived macrophages 
isolated from healthy mice (Gomez-Munoz, Kong et al. 2004). Since the first biological 
activity of C1P relating to DNA synthesis and cell division was identified (Gomez-Munoz, 
Duffy et al. 1995, Gomez-Munoz, Frago et al. 1997), researchers have found that this 
phospholipid was attributed to various vital functions, such as macrophage proliferation 
and migration (Granado, Gangoiti et al. 2009, Gangoiti, Granado et al. 2010), 
phagocytosis (Hinkovska-Galcheva, Boxer et al. 1998), inflammation (Pettus, Bielawska 
et al. 2003, Pettus, Bielawska et al. 2004) and cell protection (Gomez-Munoz, Kong et al. 
2004, Gomez-Munoz, Kong et al. 2005). However, it has not been revealed yet whether 
C1P could inhibit cochlear hair cell death induced by cisplatin. 
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Induction of cell death is a complex process and tightly regulated. In the present study 
we hypothesized that C1P could be an antiapoptotic molecule and that targeted ceramide 
– C1P balance could interfere cochlear cell survival.  
 
2.2. Methods  
2.2.1. Culture technique 
2.2.1.1. Cochlear explants 
The lower basal turn of the organ of Corti was dissected from C57BL/6J mouse on 
postnatal days 3 (P3) to 5 (P5) and cultured according to the methods of Van de Water 
and Ruben (Van de Water and Ruben 1974) and Sobkowicz et al. (Sobkowicz, Loftus et 
al. 1993). In brief, after sterilized, a mice pup were decapitated. The ear capsule was 
quickly exposed and taken out. The organ of Corti housing cochlear hair cells was isolated 
from other structure and was transferred to culture media. All animal procedures were 
carried out according to the guidelines of the Laboratory Animal Research Center of 
Tsukuba University (Fig. 2.2) 
 
Figure 2.2. Scheme of experimental design 
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2.2.1.2. Culture techniques 
The organs of Corti (cochlear explants)  were maintained in a culture medium 
containing Dul-becco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum (FBS), 
25 mM HEPES, and 30 U/mL penicillin. They were cultured in an incubator at 37oC with 
5% CO2 at 95% humidity. Cochlear explants were maintained in culture medium 
overnight (8 – 12 hours) and then were exposed to a new culture medium containing 
tested agents (e.g. cisplatin, C1P, or NVP-231 … ) for 48 hours (Tabuchi, Pak et al. 2007). 
 
2.2.1.3. Cisplatin treatment 
Cisplatin (Nichi-Iko, Sogawa, Japan) was used in a form of commercial liquid.  
Cisplatin-induced ototoxicity was characterized by the missing of cochlear OHCs at the 
basal turn of the organ of Corti. Before conducting this study, we examined the damage 
of cochlear OHCs by exposing cochlear explants to several concentrations of cisplatin 
from 1 to 50 μM. The concentrations of cisplatin at 5 and 10 μM were chosen for the 
present experiments. 
 
2.2.1.4. C1P treatment 
C1P (Sigma, St. Louis, MO, USA) was initially dissolved in ethanol at a concentration 
of 2 mg/ml, and was routinely stored at -20 oC. Before used, C1P was diluted in the culture 
medium to the final concentrations. After the cochlear explants were stabilized in the 
culture medium overnight, each group (from 9 to 18 cochlear explants) was exposed to 
culture media containing 10 μM cisplatin plus various concentrations of C1P (from 1 to 
100 μM) for 48 hours. 
12 
 
2.2.1.5. Ceramide treatment 
C16-ceramide (LKT Laboratories, St. Paul, MN, USA) was dissolved in ethanol at a 
concentration of 5 mg/ml and was stored at -20 oC. The effect of ceramide alone on 
cochlear explants was tested using concentrations from 10 to 500 μM. Later, the 
combination of 5 μM cisplatin and various concentrations of ceramide (from 10 to 500 
μM) was examined. In another condition, 500 μM ceramide was selected to mix with 
various concentrations of NVP-231 (from 10 to 200 μM), and this combination was applied 
to assess the survival of cochlear OHCs. In all experiments, cochlear explants were 
stabilized in the normal culture medium overnight before treated in different conditions for 
48 hours.  
 
2.2.1.6. NVP-231 treatment 
NVP-231 was dissolved in dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA) 
at a concentration of 10 mg/ml, and was stored at 4 oC. Control experiments were 
conducted by treating cochlear hair cells with NVP-231 ranging from 10 to 200 μM. Next, 
cochlear explants, which were stabilized in the culture medium overnight, were exposed 
to culture media containing 5 μM cisplatin plus various concentrations of NVP-231 (from 
0.1 to 10 μM) for 48 hours. 
 
2.2.2. Cytochemistry 
At the end of the tissue culture, cochlear explants were fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS) for 20 minutes and then 
permeabilized with 5% Triton X-100 (Sigma, St. Louis, MO,USA) in PBS with 10% fetal 
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bovine serum for 10 minutes. The specimens were stained with phalloidin using a 
conjugated Alexa Fluor probe (1:100, Molecular Probes, Carlsbad, CA, USA) at room 
temperature for 1 hour (Tabuchi, Pak et al. 2007). Phalloidin is a specific marker for 
cellular F-actin and labels stereociliary arrays and the cuticular plates of hair cells. The 
specimens were observed using a confocal microscope (FluoView F10i, Olympus, Center 
Valley, PA, USA). Hair cells were characterized as missing if no stereocilia or no cuticular 
plates were observed by phalloidin staining. Quantitative results were obtained by 
evaluating 30 OHCs associated with 10 inner hair cells in a given microscopic field. The 
average of three randomly separated counts was used to represent each tissue culture. 
Residue of cochlear OHCs was expressed as a percentage and the results of each the 
groups were compared (Tabuchi, Pak et al. 2007). 
 
2.2.3. Western blots  
After collected using the same methods described above, the organs of Corti were 
treated in culture media alone or in culture media containing either 10 μM cisplatin or 10 
μM cisplatin plus 100 μM C1P for 24 or 48 hours. Explants were then homogenized in 
Pro-Prep protein extraction solution (iNtRON, Kyungki, Korea) following the product’s 
protocol. After centrifuged at 13,000 rpm at 4oC for 10 minutes, the supernatant was 
transferred to a fresh tube and the protein content was measured by using protein assay 
rapid kit (Wako, Osaka, Japan). Equal amounts of lysate protein (20 μg) were mixed with 
equal volumes of sample buffer (100 mM Tris–HCl, pH 6.8, 4% SDS, 20% glycerol, 10% 
2-mercaptoethanol, and 0.02% bromophenolblue), heated at 95 oC for 5 min, and then 
subjected to SDS–PAGE using 4%-20% mini-PROTEAN TGX precast polyacrylamide gel 
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(Bio-Rad, Hercules, CA, USA). The proteins were transferred by means of a semidry 
electroblotting system from the gels to Hybond polyvinylidene difluoride membrane (GE 
Healthcare, Buckinghamshire, UK) for 1 hour. Skim milk powder was used for blocking 
buffer. After blocking, each membrane was primarily treated with polyclonal antibodies 
Akt (1:500), pAkt (1:500), ERK1/2 (1:500), or pERK1/2 (1:500) overnight at 4oC. 
Horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (1:2000) was 
secondarily treated for 1 hour at room temperature. The antibodies described above were 
purchased from Cell Signaling Technology (Beverly, MA, USA). Chemiluminescent 
detection was enhanced with ECL kit (GE Healthcare, Buckinghamshire, UK) and the 
immunoblot images were obtained with the ImageQuant LAS4000 mini imager (GE 
Healthcare, Buckinghamshire, UK). Densitometric analysis was done from at least 3 
independent experiments by using ImageJ software (Nation Institutes of Health).  
 
2.2.4. Data analysis 
All data were expressed as the means ± SDs. Statistical analysis was performed by t-
test or one-way analysis of variance (ANOVA) followed by Bonferroni post hoc tests, as 
required (SPSS 20). Probability values less than 0.05 were considered significant. 
 
2.3. Results 
2.3.1. Control study 
A series of concentrations from 2 to 50 μM was selected to test the ototoxicity of 
cisplatin on OHCs. The results showed that there were significant differences among 
cisplatin groups (Fig. 2.3; ANOVA followed by Bonferroni post hoc test; P < 0.05 among 
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groups), and it also suggested that cisplatin has a dose-dependent effect on OHCs. From 
the obtained data, concentrations of 5 and 10 μM were selected for next appropriated 
purposes of this study. 
 
Figure 2.3. Effect of different concentrations of cisplatin on cochlear OHCs.  
The survivals of cochlear OHCs were around 93.5 %, 77.1%, and 31% corresponding to 
2, 5, and 10 μM cisplatin, respectively. Cochlear hair cells were completely destroyed at 
50 μM cisplatin. (ANOVA followed by Bonferroni post hoc test, P <0.05) 
 
The effects of 100 μM C1P, 10 μM NVP-231 or solvents alone (1% ethanol and 0.04% 
DMSO) on cochlear OHCs were examined. After 48-hour exposure to above agents, all 
of cochlear OHCs remained intact. (Fig. 2.4) 
100 μM C1P 10 μM NVP-231 
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1% ethanol 0.04% DMSO 
  
 
Figure 2.4. Effect of C1P, NVP-231 and solvent on cochlear OHCs 
 
In addition, the interactions between cisplatin and solvents were also checked. There 
were no significant differences in cochlear hair cell loss between explants treated with 
cisplatin alone and one treated with cisplatin plus either 1% ethanol or 0.04% DMSO; the 
tested concentrations of cisplatin were 10 μM (Fig. 2.5) 
(A) 
 
(B) (C) 
  
(D) 
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Figure 2.5. Effect of cisplatin with the addition of solvents.  
(A) Quantitative analysis of cochlear OHCs (ANOVA followed by Bonferroni post hoc 
test, P >0.05). (B) 10 μM cisplatin. (C) 10 μM cisplatin plus 1% ethanol. (D) 10 μM 
cisplatin plus 0.04% DMSO. CDDP: cisplatin 
 
2.3.2. C1P and the survival of OHCs in cisplatin ototoxicity 
We examined the effect of C1P on cisplatin-induced OHC damage. The results 
revealed a dose-dependent relationship between C1P treatment and the survival of 
cochlear OHCs. When compared with cisplatin treatment alone, the addition of C1P 
treatment significantly increased the survival of cochlear OHCs at 10 μM C1P or higher 
(Fig. 2.6; ANOVA followed by Bonferroni post hoc test; 10 μM-C1P group, n = 16, P = 
0.014; 30 μM-C1P, n = 18, P = 0.03; 100 μM-C1P, n = 9, P = 0.007; n is the number of 
cochlear explants). 
(A) 
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(B) (C) 
  
(D) (E) 
  
(F) (G) 
  
 
Figure 2.6. Effect of C1P on the survival of cochlear OHCs in cisplatin ototoxicity.  
(A) Quantitative analysis of cochlear OHCs. The survival of cochlear OHCs significantly 
increased at 10 μM C1P or higher (ANOVA followed by Bonferroni post hoc test, *P < 
0.05). (B – G) Representative photographs of each group (scale bar 20 μm). (B) 100 μM 
C1P alone. (C) 10 μM cisplatin alone. (D) 10 μM cisplatin and 1 μM C1P. (E) 10 μM 
cisplatin and 10 μM C1P. (F) 10 μM cisplatin and 30 μM C1P. (G) 10 μM cisplatin and 
100 μM C1P. CDDP: cisplatin. 
 
2.3.3. C1P and phosphorylation of Akt and ERK1/2 
The above results suggested that C1P could inhibit cochlear OHC death induced by 
cisplatin. Next, Western blots were conducted to determine whether this effect of C1P 
involves the stimulation of the PI3-K/Akt or ERK1/2 pathway. Cochlear explants were 
treated in 3 different conditions, including the culture medium alone, 10 μM cisplatin, or 
10 μM cisplatin plus 100 μM C1P. Immunoblot images revealed strong activations of Akt 
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(Fig. 2.7A, 2.7C) and ERK1/2 (Fig. 2.7E) in cochlear explants treated with C1P. In addition, 
densitometric analysis also revealed significant increases of pAkt in a group of C1P 
addition compared to a group without C1P for 24 hours (Fig. 2.7B; t-Test , P = 0.005) or 
48 hours (Fig. 2.7D; t-Test, P = 0.025). The signal of pERK1/2 was also significantly 
increased when C1P was added for 48 hours (Fig. 2.7F; t-test, P = 0.015) 
(A) (B) 
 
  +C1P   
 Control CDDP CDDP 
 24h 24h 24h 
 
 pAkt 
 Akt 
 
 (C) (D)  
 
  +C1P   
 Control CDDP CDDP 
 48h 48h 48h 
 
 pAkt 
 Akt 
 
 
(E) (F) 
 
  +C1P   
 Control CDDP CDDP 
 48h 48h 48h 
 
 
pERK1/2 
 
ERK1/2 
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Figure 2.7. Representative Western blots of pAkt, total Akt, pERK1/2 and total ERK1/2. 
Comparisons were conducted among 3 groups: control group (no cisplatin), 10 μM 
cisplatin plus 100 μM C1P group, and 10 μM cisplatin group. (A) Chemiluminescent 
detection of pAkt and Akt with 24-hour treating time. (C) Chemiluminescent detection of 
pAkt and Akt with 48-hour treating time. (E) Chemiluminescent detection of pERK1/2 
and ERK1/2 with 48-hour treating time. (B, D, F) C1P significantly increased 
densitometric signals of pAkt and pERK1/2 in comparison to groups without C1P (t-test, 
P < 0.05). Densitometric values were normalized to values of control group. pAkt and 
pERK1/2 have been referenced to total Akt and total ERK1/2, respectively. Data were 
obtained from three independent experiments. CDDP: cisplatin. 
 
2.3.4. The effect of ceramide on cisplatin-induced cochlear OHCs death 
Ceramide is a regulator of cellular apoptosis, and this experiment was conducted to 
show whether or not ceramide amplifies cisplatin-induced hair cell death. First, ceramide 
alone was examined on cochlear explants. All cochlear OHCs were intact at 200 μM 
ceramide or lower, and very few hair cells were lost at 500 μM (Fig 2.8). Later, several 
concentrations of ceramide as above were tested with 5 μM cisplatin addition. Only the 
condition of 500 μM ceramide plus 5 μM cisplatin significantly decreased the number of 
cochlear OHCs (Fig. 2.9; ANOVA followed by Bonferroni post hoc test; n = 9, P < 0.001 
at 500 μM). 
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(A) 
 
(B) (C) 
  
(D) (E) 
  
 (F) 
  
 
Figure 2.8. Effects of ceramide on cochlear OHCs. 
(A) Quantitative analysis of cochlear OHCs. All cochlear OHCs were intact with 
ceramide concentration lower than 200 μM and few were lost at 500 μM. (B – F) 
Representative photographs of each group (scale bar 20 μm). (B) 10 μM ceramide. (C) 
30 μM ceramide. (D) 100 μM ceramide. (E) 200 μM ceramide. (F) 500 μM ceramide. 
Cer: ceramide. 
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(A) 
 
(B) (C) 
  
(D) (E) 
  
(F) 
 
 
Figure 2.9. Effects of ceramide on cisplatin-induced cochlear OHC death.  
(A) Quantitative analysis of cochlear OHCs. The residue of cochlear OHCs decreased 
significantly at 500 μM ceramide (ANOVA followed by Bonferroni post hoc test, *P < 
0.001). (B – F) Representative photographs of each group (scale bar 20 μm). (B) 5 μM 
cisplatin alone. (C) 5 μM cisplatin and 10 μM ceramide. (D) 5 μM cisplatin and 100 μM 
ceramide. (E) 5 μM cisplatin and 200 μM ceramide. (F) 5 μM cisplatin and 500 μM 
ceramide. CDDP: cisplatin. 
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 2.3.5. CERK inhibitor and cochlear hair cell death induced by cisplatin or 
ceramide 
CERK converts ceramide to C1P and contributes to the balance of the C1P and 
ceramide levels. NVP-231, a selective CERK inhibitor, was used to evaluate the 
involvement of CERK when cochlear OHCs exposure to cisplatin or ceramide.  
Before conducting experiments in this step, series of concentrations of NVP-231 were 
tested on cochlear OHCs to evaluate its toxicity. At 10 μM NVP-231, all cochlear hair cells 
were intact. From 30 to 200 μM NVP-213, very few cochlear hair cells were loss and there 
were no statistical difference among groups (Fig. 2.10) 
(A) 
 
(B) (C) 
  
(D) (E) 
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Figure 2.10. Effect of NVP-231 on cochlear OHCs.  
(A) Quantitative analysis of cochlear OHCs (ANOVA followed by Bonferroni post hoc 
test, P >0.05). (B) 10 μM NVP-231. (C) 30 μM NVP-23. (D) 100 μM NVP-23. (E) 200 μM 
NVP-23 
 
At  first, 5 μM cisplatin was mixed with  to several concentrations of NVP-231. OHC 
cell death induced by 5 μM cisplatin was significantly exacerbated in the presence of 
NVP-231 at 3 μM or higher (Fig. 2.11; ANOVA followed by Bonferroni post hoc test; 3 μM 
NVP-231 group, n = 10, P = 0.008; 10 μM NVP-231 group, n = 10, P = 0.005). Later, in a 
different condition, 500 μM ceramide was combined with several concentrations of NVP-
231. OHC death was severely damaged, starting with 10 μM NVP-231, and OHCs were 
completely unable to identify at 200 μM (Fig. 2.12; ANOVA followed by Bonferroni post 
hoc test; 10 μM NVP-231 group, n = 9, P = 0.000; 30 μM NVP-231 group, n = 10, P = 
0.000; 100 μM NVP-231 group, n = 9, P = 0.000) 
 
(A) 
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(D) (E) 
  
(F) 
 
 
Figure 2.11. Effects of NVP-231 on cisplatin-induced OHC death.  
(A) Quantitative analysis of cochlear OHCs. The survival of cochlear OHC was 
statistically decreased through the effect of 3 μM NVP-231 or higher (ANOVA followed 
by Bonferroni post hoc test, *P < 0.05). (B – F) Representative photographs of each 
group (scale bar 20 μm). (B) 10 μM NVP-231 alone. (C) 5 μM cisplatin alone. (D) 5 μM 
cisplatin and 1 μM NVP-231. (E) 5 μM cisplatin and 3 μM NVP-231. (F) 5 μM cisplatin 
and 10 μM NVP-231. CDDP: cisplatin. 
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(A) 
 
(B) (C) 
  
(D) (E) 
  
(F) 
 
 
Figure 2.12. Effects of NVP-231 on cochlear hair cell treated with ceramide.  
(A) Quantitative analysis of cochlear OHCs. The survival of cochlear OHCs was 
statistically decreased when NVP-231, starting from 10 to 200 μM, was added to culture 
media containing 500 μM ceramide (ANOVA followed by Bonferroni post hoc test, *P = 
0.000). (B – F) Representative photographs of each group (scale bar 20 μm). (B) 500 
μM ceramide alone. (C) 500 μM ceramide and 10 μM NVP-231. (D) 500 μM ceramide 
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and 30 μM NVP-231. (E) 500 μM ceramide and 100 μM NVP-231. (F) 500 μM ceramide 
and 200 μM NVP-231; all explants were severely damaged. Cer: ceramide. 
 
2.4. Discussion 
It has been demonstrated that C1P participates in several vital pathophysiological 
functions including regulation of cell growth and survival, stimulation of DNA synthesis 
and cell division, and inhibition of cellular apoptosis (Gomez-Munoz, Frago et al. 1997, 
Carpio, Stephan et al. 1999, Gomez-Munoz 2004). Previous studies also suggested that 
functions of C1P might be specific to cell types. In the present study, its involvement in 
cisplatin-induced hair cell death was investigated. This is the first time we showed that 
cisplatin-induced cochlear OHC death was successfully suppressed by using C1P. 
Previously, C1P was acknowledged for its anti-apoptotic potential, but in different 
experiment conditions from ours. Gomez-Munoz laboratory showed that additional C1P 
treatment to culture media without macrophage colony-stimulating factor blocked the 
activation of caspase, prevented DNA fragmentation, and led to stability of macrophage 
viability (Gomez-Munoz, Kong et al. 2004). Earlier, Frago et al  also recorded the effect 
of C1P in suppression of starvation-induced cell death (Frago, Leon et al. 1998).  
In the first few hours of cisplatin exposure, cochlear hair cells enhance their defence 
mechanisms by inducing the upregulation of several anti-apoptotic genes that are 
associated with the NF-κB pathway, caspase recruitment domain family, IAP family, Bcl-
2 family, and p53 signaling (Ding, Ping et al. 2009). These signaling pathways are also 
known to be stimulated by the PI3-K/Akt pathway. Our study revealed that activation of 
the PI3-K/Akt pathway was at least one of the mechanisms in which C1P promotes 
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cochlear hair cell survival. Previous studies pointed to sphingomyelin as the major 
precursor for ceramide and to sphingomyelinase as the major enzyme responsible for 
ceramide generation. The activity of sphingomyelinase was reportedly restrained through 
the activation of PI3-K/Akt pathway (Testai, Landek et al. 2004) and prevented the 
increase of ceramide (Noda, Yoshimura et al. 2001) as its result. Another supportive 
result came from an experiment using sphingomyeline assay to measure activities of 
sphingomyelinase, and authors also pointed out that the introduction of C1P lowered 
sphingomyelinase activity. Moreover, their results indicated that C1P involved direct 
physical interaction with sphingomyelinase as it inhibited this enzyme in cell homogenates 
(Gomez-Munoz, Kong et al. 2004). Additionally, the activation of ERK1/2 pathway, which 
is related to cell growth-survival, could be another explanation of cochlear hair cell 
survival in our study (Fig. 2.13). ERK1/2 are critical components of the intracellular 
signaling networks that regulate gene expression in response to cisplatin, and ERK1/2 
activation determined cell fate in response to cisplatin (Brozovic and Osmak 2007). In 
fact, the induction of ERK1/2 phosphorylation was reported in experimental models of 
C1P with osteoblastic cells (Carpio, Stephan et al. 1999) and macrophages (Gangoiti, 
Granado et al. 2008).  
29 
 
 Figure 2.13. Activation of Akt and ERK1/2 pathway induced by C1P and its relation 
to cochlear hair cell survival 
 
The co-administration of ceramide and cisplatin accelerated the death of cochlear 
OHC at high concentration in our study. It was known that cisplatin activated acid 
sphingomyelinase and released ceramide (Lacour, Hammann et al. 2004); therefore, it 
leaded to the excessive accumulation of ceramide, and could be one of explanations for 
the effects of this co-administration. Ceramide was known to cause the death of neuronal 
cells in the central and peripheral nervous systems (Cavallini, Venerando et al. 1999, Yen, 
Mar et al. 1999, Carpinteiro, Dumitru et al. 2008). Although precise mechanisms of 
ceramide induced-cell death have not fully known yet, it is currently thought that its 
mechanisms were related to activation of apoptotic processes (e.g., PKC, PP2A, etc.) 
(Ruvolo 2003), and also to inhibition of anti-apoptotic pathway (Zundel, Swiersz et al. 
2000). 
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In the present study, ceramide alone had least effects on cochlear hair cells. In 
mammalian cells, CERK directly phosphorylates ceramide to synthesize C1P and is 
currently the only known enzyme to have this function (Sugiura, Kono et al. 2002). 
Therefore, we hypothesized that cochlear hair cells might have a high intrinsic activity of 
CERK, which rapidly phosphorylates ceramide resulting in increase of C1P synthesis; 
thus, cochlear hair cells were protected from the damage of high ceramide concentration. 
When treating cochlear hair cells with NVP-231 (a CERK inhibitor) in the presence of 
cisplatin or ceramide, we observed remarkable increases of apoptosis. It was the 
consequence of at least two processes: inhibition of ceramide phosphorylation and 
disinhibition of acid sphingomyelinase (Testai, Landek et al. 2004), which lead to the 
accumulation of ceramide and depletion of C1P. Although the measurement of C1P could 
not be archived due to its scantiness in cochlear explants, these results confirmed our 
hypothesis above and explained partly the central role of C1P in governing cochlear hair 
cell fate. 
Taken together our results suggest the importance of the balance between ceramide 
and C1P. On one hand, ceramides triggers apoptosis via several pathways including 
blocking the PI3-K/Akt; on the other hand, C1P inhibits this process by activating the PI3-
K/Akt pathway and increasing phosphorylation of ERK1/2. In short, our present study 
suggests that at least the balance of ceramide and C1P regulates cochlear hair cell fate, 
and any circumstances that alter this balance (e.g., a CERK inhibitor) will affect the 
survival of cochlear hair cell (Fig. 2.14). 
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 Figure 2.14. Outer hair cell fate and ceramide – C1P balance 
 
Since the discovery of CERK over 10 years ago, some evidences showed that 
inhibition of CERK might enhance the efficacy of anti-cancer therapies. Firstly, 
significantly high expression of CERK was identified in estrogen-receptor-negative breast 
cancer tumors (Ruckhaberle, Karn et al. 2009) and hepatoma cell lines (Hsieh, Hsu et al. 
2009). Secondly, when the activity of CERK is abolished, it greatly increases the 
susceptibility of tumor cell lines to low-dose UV irradiation (Hsieh, Hsu et al. 2009). 
Furthermore, it is suggested that the inhibition of CERK will overcome the issue of 
chemotherapeutic resistance by rising ceramide levels in combination of chemotherapies 
(Ogretmen and Hannun 2004). However, the inhibition of CERK needs to be approached 
with great caution, because of a possibility of an unbalance between ceramide and C1P. 
The elevation of ceramide level would possibly render other normal cells more vulnerable 
to the treatment – particularly cochlear hair cells in cisplatin ototoxicity, as the findings of 
our study.  
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2.5. Conclusion 
Relied on  published results, some authors  recommended that effects of C1P might 
be cell type-specific, and this is the first time we provides evidences that C1P regulates 
cochlear hair cell survival in cisplatin ototoxicity through the PI3-K/Akt and ERK1/2 
pathway. In addition, the data pointed out that this survival follows the balance of 
ceramide and C1P. Cisplatin and CERK inhibitor are some of the factors shifting this 
balance to the ceramide side. While the former was known to increase ceramide level by 
activating its generation, the latter inhibits the phosphorylation process leading to the 
increase of ceramide accumulation. In contrast, this balance will move to C1P side when 
there is an endogenous or exogenous acceleration of C1P. 
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Chapter 3. The role of peroxiredoxin I in cisplatin-induced 
ototoxicity 
3.1. Introduction 
Peroxiredoxins (Prxs) are a family of small antioxidative proteins from 22 to 27 kDa 
(Kim, Kim et al. 1988, Chae, Kim et al. 1993). To date, 6 Prx subtypes have been identified 
in mammals (Knoops, Clippe et al. 1999, Seo, Kang et al. 2000), and can be divided into 
three major subclasses: typical 2-cysteine Prxs (Prx 1 to 4), atypical 2-cysteine Prx (Prx 
5) and 1-cysteine Prx (Prx 6).  
Prxs have been shown to be related to diverse cellular roles (Rhee and Woo 2011), 
among which scavenging reactive oxygen species (ROS) via reducing equivalents has 
generated a great interest. Particularly, Prxs catalyze the reduction in hydrogen peroxide, 
alkyl hydroperoxides, and peroxynitrite using reducing equivalents provided by 
thioredoxin (Hofmann, Hecht et al. 2002). Among the 6 subtypes, Prx I is found mainly in 
the cytosol and is ubiquitously expressed in various tissues (Uwayama, Hirayama et al. 
2006); for example, it is highly expressed in the liver, kidney, and small intestine (Ishii, 
Yamada et al. 1993, Ishii, Itoh et al. 2000). The major roles of the Prxs are related to 
cellular protection against oxidative stress, to the modulation of intracellular signaling 
cascades using hydrogen peroxide as a second messenger, and to the regulation of cell 
proliferation. Expression of the Prx I gene is upregulated by various stress agents and is 
considered to be a cellular recovery response (Ishii, Yamada et al. 1993, Chang, Jeong 
et al. 2002). In a previous study conducted by our colleagues (Uwayama, Hirayama et al. 
2006), the liver and kidney of the Prx I-deficient mouse were significantly sensitive to 
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increases in ROS, and we therefore hypothesized that a similar phenomenon may also 
be present in the mouse cochlea.  
As we described in a previous chapter, cisplatin is well known as a chemotherapeutic 
agent against malignant tumors (Boulikas and Vougiouka 2004). Regardless of its 
efficiency, its clinical application is often limited by the associated side effects. Of these, 
ototoxicity is one of the most serious concerns because of the risk of permanent hearing 
loss associated with cochlear damage. The ototoxic mechanisms of cisplatin have 
gradually been identified, and oxidative stress has been implied as one of the main 
pathophysiologies (Rybak, Whitworth et al. 2007, Goncalves, Silveira et al. 2013). Animal 
research indicates that reduced auditory acuity is partially mediated by free radical 
generation and antioxidant inhibition (Evans and Halliwell 1999). Other in vitro 
experiments showed that cisplatin raises ROS levels and depletes the intracellular 
concentration of glutathione (Hanigan and Devarajan 2003), and lead to cell apoptosis 
(Ueda, Kaushal et al. 2000). It is well known that antioxidative enzymes (eg, superoxide 
dismutase and glutathione peroxidase) are essential to scavenge the ROS involved in the 
oxidative stress induced by cisplatin to protect cells from further damage. Therefore, 
various kinds of antioxidant therapies have been tried to ameliorate the ototoxicity of 
cisplatin (Li, Frenz et al. 2001, Teranishi and Nakashima 2003). However, less is known 
about the involvement of Prxs in the cochlea.  
In the present study, we examined the expression of Prx subtypes in the mouse 
cochlea and showed how Prx I participates in protecting the cochlea against cisplatin 
through comparing effects of cisplatin on wildtype mice and Prx I-deficient mice.  
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3.2. Method  
3.2.1. Animals and cochlear explants  
C57BL/6J mice and Prx I-deficient mice from postnatal days 3 to 5 were used. Prx 
I-deficient mice were generated as described previously (Uwayama, Hirayama et al. 
2006). For the cochlear explants, we used basal turns of the organ of Corti dissected and 
cultured according to the methods of Van de Water and Ruben (Van de Water and Ruben 
1974) and Sobkowicz et al (Sobkowicz, Loftus et al. 1993). All animal procedures were 
conducted according to the guidelines of the Laboratory Animal Research Center of the 
University of Tsukuba. 
 
3.2.2. Cisplatin treatment 
Cochlear explants from both wildtype and Prx I-deficient mice were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 
25 mM HEPES, and 30 U/mL penicillin. The cultures were incubated at 37oC with 5% 
CO2 at 95% humidity. The cochlear explants were initially stabilized in the above-
described medium overnight (8 – 12 hours) before transferred to a new medium plus 2, 
5, or 10-μM cisplatin for 48 hours. 
 
3.2.3. Cytochemistry 
At the end of the culture process, each experimental group, which consisted of 11 
to 12 cochlear explants, was fixed with 4% paraformaldehyde in phosphate-buffered 
saline (PBS) for 20 minutes and then permeabilized with 5% Triton X-100 (Sigma, St. 
Louis, MO, USA) in PBS with 10% fetal bovine serum (FBS) for 10 minutes. The explants 
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were stained with phalloidin with a conjugated Alexa Fluor probe (1:100; Molecular 
Probes, Carlsbad, CA, USA) at room temperature for 1 hour (Tabuchi, Pak et al. 2007). 
Phalloidin is a specific marker for cellular F-actin and labels stereociliary arrays and the 
cuticular plates of hair cells. Cochlear explants were transferred to a glass slide and 
examined with a FluoView F10i confocal microscope (Olympus, Center Valley, PA, USA). 
Hair cells were characterized as missing if no stereocilia or no cuticular plates were 
observed by phalloidin staining. Quantitative results were obtained by evaluating 30 
OHCs associated with 10 inner hair cells in a given microscopic field. The average of 
three randomly separated counts was used to represent each tissue culture. The residue 
of cochlear hair cells was expressed as a percentage and the results of each group were 
compared (Tabuchi, Pak et al. 2007).  
 
3.2.4. Reverse transcription-polymerase chain reaction (RT-PCR) 
After a postnatal pup was decapitated, cochlea was dissected, ear capsule were 
removed, and three main parts of cochlea were isolated, including organ of Corti, lateral 
wall and modiolus. Total ribonucleic acids (RNA) of the organ of Corti, the modiolus, the 
lateral wall were extracted using Qiagen RNeasy mini kit (Qiagen Inc., Valencia, CA, 
USA). To avoid any DNA contaminations, DNase I (Qiagen Inc., Valencia, CA, USA) was 
added to RNA extraction column following the instruction of the supplier. Reverse 
transcription of the extracted total RNA was performed using random primer (Random 
Primers, Invitrogen), RNaseOUTTM Recombinant Ribonuclease Inhibitor (Invitrogen), and 
SuperScript® II Reverse Transcriptase (Invitrogen). The mRNA expression levels were 
detected by conventional reverse transcription polymerase chain reaction with Taq 
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polymerase enzyme (Takara, Shiga, Japan) by Veriti Thermal Cycler (Life Technologies, 
Grand Island, NY, USA). Prx primer sequences were summarized in table 3.1 and 
glyceraldehyde-3-phoshate dehydrogenase (GAPDH) was used as an internal control. All 
gene sequences were accessed from GenBank®. 
Abbreviation Names Accession number 
Forward primer Amplicon 
size (bp) Reverse primer 
Prx1 
Mus musculus 
peroxiredoxin 1 
NM_011034.4 
ACGACTAGTCCAGGCCTTCC 
GGCAGAAAAATGGTCCAGTG 
151 
Prx2 
Mus musculus 
peroxiredoxin 2 
NM_011563.5 
CTCCTGACTTCACGGCCACA 
GAAGTCCTCAGCATGGTCGCTAA 
161 
Prx3 
Mus musculus 
peroxiredoxin 3 
NM_007452.2 
GGTGCTTTTCTTCTACCCTTTGG 
CACAGTTTACATCATGAAATTCATTGG 
98 
Prx4 
Mus musculus 
peroxiredoxin 4 
NM_016764.4 
TGGACGAGACACTGCGTTTG 
CTGGATCTGGGATTATTGTTTCACTAC 
108 
Prx5 
Mus musculus 
peroxiredoxin 5 
NM_012021.2 
GGAAGGCGACAGACTTATTATTGG 
CTCCACGTTCAGTGCCTTCAC 
116 
Prx6 
Mus musculus 
peroxiredoxin 6 
NM_007453.3 
GCCAAGAGGAATGTTAAGTTGATTG 
GTTTCACCATTGTAAGCATTGATGTC 
95 
Actb 
Mus musculus 
actin, beta 
NM_007393 
CATTGCTGACAGGATGCAGAAGG 
TGCTGGAAGGTGGACAGTGAGG 
138 
GAPDH 
Mus musculus 
GAPDH 
NM_001289726.1 
TGTGTCCGTCGTGGATCTGA 
TTGCTGTTGAAGTCGCAGGAG 
150 
Table 3.1. Primer sequences for real-time PCR 
 
3.2.5. Real-time PCR assay for mRNA 
The cochlear explants of C57BL/6J mice were cultured in different conditions, 
including a normal culture medium or a culture medium plus 5-μM cisplatin for 4, 8, 24, 
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or 48 hours. Total RNAs of the cochlear explants were extracted as described above. 
Total RNA was quantitated on a NanoDrop 2000 UV-Vis spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA), and equal amounts of total RNA (140 ng) were used for 
all real-time PCR assays. mRNA was primed with random hexamers, and complementary 
DNA (cDNA) was synthesized from mRNA by using SuperScript III reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA). The cDNA was amplified by using SsoFast EvaGreen 
Supermix with Low ROX (Bio-Rad Laboratories, Hercules, CA, USA) according to the 
manufacturer’s instructions. The primers used for the real-time PCR are listed in Table 
3.1; beta actin was used as the internal control. The final mixture of the PCR reaction 
(total 20 μL) contained 1 μL of cDNA, 0.4 μL of 10 μmol/L forward primer, 0.4 μL of 10 
μmol/L reverse primer, 10 μL of Bio-Rad PCR buffer, and 9.8 μL of DEPC-treated water. 
The PCR reaction was repeated in duplicate (2 wells of a 96-well plate), and the whole 
assay was repeated in triplicate. The change in the expression of each gene was 
measured by using the ABI 7500 Fast Real-Time PCR system (Applied Biosystems, 
Foster City, CA, USA) with the optimized PCR protocol for the Bio-Rad PCR buffer. The 
relative quantification value of the expression of the gene of interest was calculated from 
the raw threshold cycle (Ct). The Ct values of beta actin were subtracted from the Ct 
values of the genes of interest to calculate the ΔCt. The ΔCt values from each 
experimental group were averaged. Values from the equation 2(-ΔCt) were used to 
compare the different expressions of the genes of interest, and the data were presented 
as the means ± SDs of the triplicate assays. 
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3.2.6. Immunofluorescence 
Immunofluorescence staining was performed to detect expression of Prx I in 
mouse cochlea. For sectioned immunofluorescence staining, both cochleae of postnatal-
day-3-to-5 and adult wildtype mice were used. Collecting method of cochlea in postnatal 
mice was described above, however adult mice had to anesthetized deeply with 
pentobarbital sodium before dissection. Cochlea with intact capsule was fixed with 4% 
paraformaldehyde, decalcified with EDTA, and then embedded in paraffin. The cochleae 
were cut into 4-μm-thick midmodiolar sections. After deparaffinized, sections was 
immersed in citrate buffer and heated in a microwave before proceeding other 
immunostaining steps, which were similar to whole-mount immunostaining.   
For whole-mount immunofluorescence staining, cochlear explants of wildtype mice 
were fixed with 4% paraformaldehyde for 10 minutes at room temperature. After washed 
3 times with PBS, the cochlear explants were permeabilized in 3% Triton X-100 solution 
for 30 minutes at room temperature and then washed again 3 times with PBS before 
blocked with 10% normal goat serum for 30 minutes at room temperature. Next, the 
blocking solution was removed, and the cochlear explants were rinsed with PBS before 
incubated with polyclonal rabbit anti-Prx I (1:50; #15816-1-AP; ProteinTech Group, 
Chicago, IL, USA) for 72 hours at 4oC. After cochlear explants were washed 3 times with 
PBS, the goat anti-rabbit secondary antibody conjugated to an Alexa Fluor 488 probe 
(1:200; #4412; Cell Signaling Technology, Beverly, MA, USA) was applied overnight at 
4oC in darkness. For fluorescence visualization of the hair cell structure, the cochlear 
explants were incubated with rhodamine phalloidin (1:100; Invitrogen) at room 
temperature for 60 minutes. The cochlear explants were mounted on slides with antifade 
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solution and examined using a FluoView F10i confocal microscope (Olympus). The same 
procedure was repeated more than 3 times to confirm the results. 
 
3.2.7. Assessment of spiral ligament fibrocytes  
Cochleae of postnatal-day-3-to-5 wildtype and Prx I-deficient mice were collected. 
After the bony capsule was gently removed, the cochlear samples were cultured for 48 
hours in media containing 5, 10, 20, 50, or 100-μM cisplatin. The cochlear samples were 
fixed with 4% paraformaldehyde and then embedded in paraffin. The cochlear samples 
were cut into 4-μm-thick midmodiolar sections. After the sections were stained with 
hematoxylin and eosin, images of the sections at the same magnification (x20) were 
collected by using a BZ-X710 microscope (Keyence, Itasca, IL, USA). The quantities of 
the spiral ligament fibrocytes of lateral wall were counted from 3 random circular areas (r 
= 15 μm) in 1 section, and the same procedure was performed for 3 different sections of 
1 cochlear sample. 
 
3.2.8. Data analysis 
All data were expressed as means ± SDs. Statistical analysis was performed using 
unpaired t tests or one-way analysis of variance (ANOVA) with Bonferroni post hoc tests, 
as required (SPSS 20). Probability values less than 0.05 were considered significant. 
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3.3. Results 
3.3.1. Expression levels of the Prx subtypes 
To ensure the mRNA quality and expression, RT-PCR analysis was conducted. 
The data showed that, mRNA of 6 subtypes were presented in organ of Corti, lateral wall 
and modiolus (Fig. 3.1). Brain tissues were used as a positive control in this study due to 
its well-known expression of 6 Prx subtypes.  Next, expression of the 6 Prx subtypes in 
the cochlear explants was observed by real-time PCR at 4, 8, 24, and 48 hours following 
5-μM cisplatin treatment. After 48 hours of cisplatin exposure, subtypes I, IV, and V 
showed significant upregulations (Fig. 3.2; ANOVA with Bonferroni test; Prx I, p = 
0.00001; Prx IV, p = 0.001; Prx V, p = 0.002), while subtypes II and VI showed significant 
downregulations (Fig. 3.2; ANOVA with Bonferroni test; Prx II, p = 0.004; Prx VI, p = 
0.0001). Subtype III did not show any statistically different change. Of the 6 subtypes, Prx 
I and II were the two most abundant in terms of mRNA expression. 
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Figure 3.1. Prx subtype expression in cochleae of wildtype mice.  
RT-PCR analysis demonstrated that 6 subtypes of Prxs were expressed in the 
organ of Corti, modiolus and lateral wall. GAPDH primers served as the cDNA loading 
control. The brain tissues were used as a positive control. NC: negative control. 
 
(A) 
 
(B) (C) 
 
(D) (E) 
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(F) (G) 
 
 
Figure 3.2. The cisplatin-induced regulation of Prxs in cochleae of wildtype mice.  
(A) Different expressions of Prx subtypes after 48 hours of cisplatin exposure. 
The expression of subtypes I, IV and V increased significantly (ANOVA followed by 
Bonferroni test; *p < 0.05), while the expression of subtypes II and VI decreased 
significantly (ANOVA followed by Bonferroni test; *p < 0.05). Subtype III showed no 
significant difference. (B – G) The time course of Prx subtype expression induced by 
cisplatin through 48 hours. 
 
3.3.2. Immunofluorescence signals of Prx I in normal cochlear explants   
The location of Prx I proteins in the organ of Corti was determined by 
immunolabeling with polyclonal rabbit anti-Prx I antibodies (Fig. 3.3). Signals for the Prx 
I proteins were observed universally in the cochlea, including in the organ of Corti, the 
lateral wall, and the spiral ganglion. In the highly magnified view, Prx I was detected in 
the cochlear IHCs and OHCs and in the supporting cells. The Prx I signals in the cochlear 
IHCs and OHCs were weaker than those in the supporting cells in the whole-mount 
immunofluorescence staining. 
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(A) (B) 
  
 
(C) (D) 
  
 
(E) (F)  (G) 
   
 
Figure 3.3. Immunofluorescence of Prx I in wildtype cochlear explants. 
Representative photographs of mid-modiolar cross-section in postnatal cochlea (A – B) 
and adult cochlea (C – D); (scale bar 100 μm in A, C, and 20 μm in B, D). Prx I was 
expressed ubiquitously in organ of Corti (solid arrow), lateral wall (dashed arrow) and 
spiral ganglion (head arrow). In magnified view of the organ of Corti, Prx I was 
expressed in the cochlear IHCs (dashed arrow), OHCs (solid arrow), and supporting 
cells around and beneath hair cells. (E – G) Representative photographs of whole-
45 
 
mount immunofluorescence staining (scale bar 20 μm). (E) Prx I was immunolabeled in 
green color. (F) Rhodamine Phalloidin staining (red) for cochlear hair cell visualization. 
(G): Merged image of Prx I and cochlear hair cells. Cochlear IHCs and OHCs showed 
weaker signals than supporting cells.  OHC: outer hair cells, IHC: inner hair cells, PC: 
pillar cells. 
 
3.3.3. Cisplatin-induced cochlear hair cell loss in Prx I-deficient mice 
Cochlear explants of both wildtype and Prx I-deficient mice were treated with 
cisplatin at concentrations of 2, 5, and 10 μM for 48 hours. After the cisplatin treatment, 
the cochlear hair cells were counted. The statistical comparisons between the groups 
revealed no significant differences in the numbers of the residual OHCs (Fig. 3.4A; 
unpaired t test; 2-μM cisplatin, p = 0.26; 5-μM cisplatin, p = 0.48; 10-μM cisplatin, p = 
0.21). In addition, no differences were found in comparison of residual inner hair cells (Fig. 
3.4B; unpaired t test; 2-μM cisplatin, p = 0.35; 5-μM cisplatin, p = 0.25; 10-μM cisplatin, p 
= 0.5). 
(A) (B) 
 
 
(C) WT + CDDP 2 (D) WT + CDDP 5 (E) WT + CDDP 10 
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(F) Prx-I null + CDDP 2 (G) Prx-I null + CDDP 5 (H) Prx-I null + CDDP 10 
   
 
Figure 3.4. Cisplatin-induced cochlear hair cell loss in wildtype and Prx I-
deficient mice.  
(A – B):  Quantitative analysis of cochlear IHCs and OHCs between wildtype and 
Prx I-deficient mice. There was no statistical difference between the groups (unpaired t-
test; p > 0.05). (B – G) Representative photographs of cochlear hair cells exposed to 
cisplatin in each group (scale bar 20 μm). 2 (C), 5 (D) and 10 (E) μM cisplatin in 
wildtype mice. 2 (F), 5 (G) and 10 (H) μM cisplatin in Prx I-deficient mice. OHC: outer 
hair cells; IHC: inner hair cells; WT: wildtype; CDDP: cisplatin 
 
3.3.4. Vulnerability of spiral ligament fibrocytes to cisplatin in Prx I-deficient mice 
Next, the density of the spiral ligament fibrocytes in the midmodiolar sections of 
postnatal-day-3-to-5 wildtype and Prx I-deficient mice were calculated. To ensure unified 
data collection, the upper basal turns of the cochlea were selected (Fig. 3.5). Cisplatin 
decreased the fibrocytes in both the wildtype and the Prx I-deficient mice. Quantitative 
analysis of the fibrocytes revealed that the number of residual fibrocytes was significantly 
more decreased in the Prx I-deficient mice than in the wildtype mice after 5, 10 and 20-
μM cisplatin exposure (unpaired t test; p = 0.00005; p = 0.002; p = 0.001 respectively). 
Meanwhile, at higher concentrations of cisplatin, cisplatin damaged the fibrocytes 
severely and no statistical differences were found between the groups (unpaired t test; 
50-μM cisplatin, p = 0.239; 100-μM cisplatin, p = 0.791) 
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(A) 
 
 
(B) WT + CDDP 5 (C) Prx-I null + CDDP 5 
  
 
(D) WT + CDDP 10 (E) Prx-I null + CDDP 10 
  
 
(F) WT + CDDP 20 (G) Prx-I null + CDDP 20 
  
 
(H) WT + CDDP 50 (I) Prx-I null + CDDP 50 
48 
 
  
 
(J) WT + CDDP 100 (K) Prx-I null + CDDP 100 
  
 
Figure 3.5. Vulnerability of spiral ligament fibrocytes in Prx I-deficient mice.  
(A) Density of spiral ligament fibrocytes in lateral wall between wildtype and Prx I-
deficient mice. The densities were calculated by number of cells per a circular area (r = 
15 μm). Prx I-deficient mice had significantly lower density at 5, 10 and 20 μM cisplatin 
(unpaired t-test; *p < 0.05); meanwhile, no differences were found at 50 and 100-μM 
(unpaired t-test; p > 0.05). (B – K) Representative photographs of spiral ligament 
fibrocytes exposed to cisplatin in each group (scale bar 20 μm). 5 (B), 10 (D), 20 (F), 50 
(H) and 100-μM (J) cisplatin in wildtype mice. 5 (C), 10 (E), 20 (G), 50 (I) and 100-μM 
(K) cisplatin in Prx I-deficient mice. WT: wildtype; CDDP: cisplatin 
 
3.4. Discussion 
The antioxidative function of Prx has been shown to be related to the pathologies of 
diseases in various organ systems; however, little is known about its role in the otologic 
system.  
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In this present study, we first showed the mRNA expression of all 6 subtypes of Prxs 
in the mouse organ of Corti and that Prx I and II were the 2 most abundant subtypes. 
Godoy et al used immunohistochemistry to build a redox atlas of the mouse and showed 
that several mouse organs expressed all 6 Prx subtypes (Godoy, Funke et al. 2011). 
However, the predominance of each Prx subtype differed from organ to organ. Although 
Prx I was wildly expressed in most of the organs and tissues, Prx I is not necessarily 
always the most abundant subtype. For example, Prx I was strongly expressed in the 
central nervous system whereas Prx II was dominantly expressed in the heart, skeleton, 
and uterus (Immenschuh and Baumgart-Vogt 2005, Godoy, Funke et al. 2011). Therefore, 
the higher expression of Prx II than of Prx I in our study may be a characteristic Prx 
expression pattern in the organ of Corti. Besides, more important conclusions of both the 
Godoy and the Immenschuh studies (Immenschuh and Baumgart-Vogt 2005, Godoy, 
Funke et al. 2011) were that different cell types of a same organ had different expressions 
of the 6 Prx subtypes. 
When the organ of Corti was exposed to cisplatin, the mRNAs of Prx I, IV, and V were 
upregulated. Similarly, in the study of Cho et al, mRNAs of Prx I and V were also 
upregulated in cisplatin-induced hepatotoxicity (Cho, Singh et al. 2012). Furthermore, 
experiments with other cell lines showed that the upregulation of Prx I was not limited to 
cisplatin but extended to various other oxidative stimuli (Ishii, Yamada et al. 1993, Bast, 
Wolf et al. 2002, Kim, Manevich et al. 2003). On the other hand, we also recognized the 
mRNA downregulation of Prx II and VI in the organ of Corti after cisplatin exposure. 
Dahlan et al (Dahlan, Karsani et al. 2012) showed that Prx II and VI of lymphocytes were 
downregulated in response to H2O2. Prx II is expressed exclusive in neurons (Sarafian, 
50 
 
Verity et al. 1999), and its abundance in cochlea may contribute to protect neuronal 
structures against oxidative stimuli. Although the exact molecular mechanism of Prx II 
down-regulation remains unclear, its down-regulation was reported to be produced by 
overoxidation induced by stimuli such as cisplatin or H2O2 (Dahlan, Karsani et al. 2012). 
Prx VI was also downregulated in response to stress stimuli in hepatocytes (Roede, 
Stewart et al. 2008) or lens epithelial cells (Pak, Kim et al. 2006). Therefore, the reaction 
of an individual Prx subtype to harmful stimuli may be conserved from cell to cell. 
In this study we used Prx I-deficient mice to understand role of Prx I in cisplatin 
ototoxicity. The expression of Prx I was confirmed by RT-PCR results above and 
immunohistochemistry findings of whole-mount tissues and sectioned tissues, which 
shows its ubiquitous expression in cochlea. Cohclear hair cells and lateral wall of cochlea 
were at least two major targets of cisplatin (van Ruijven, de Groot et al. 2005, van Ruijven, 
de Groot et al. 2005)  and they were selected to examine. We found that spiral ligament 
fibrocytes of the lateral wall significantly decreased after cisplatin exposure in Prx I-
deficient mice; meanwhile, no statistical difference was found in outer and inner hair cell 
loss. Our finding for spiral ligament fibrocytes is supported by the study of Ma et al, who 
showed that fibroblasts, also derived from the embryos of Prx I-deficient mice, were 
vulnerable to cisplatin-induced apoptosis (Ma, Warabi et al. 2009), and ultraviolet 
radiation (Ito, Kimura et al. 2013). At least one possible explanation for the difference in 
the results between cochlear hair cells and spiral ligament fibrocytes in cisplatin 
ototoxicity is that different origins of these cells  leads to different roles for the Prx 
subtypes. As mentioned above, Godoy study showed that different cell types have 
different expressions of Prx subtypes, although these cell types involve a same organ, 
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and this finding was proved in most of organs (Godoy, Funke et al. 2011). Similarly, in the 
review of Immenschuh, the author collected information from many studies and concluded 
that individual Prxs were found to have a characteristic cell-type and organ-specific 
expression pattern (Immenschuh and Baumgart-Vogt 2005). One of the examples is that 
Prx I showed moderate expression level in proximal tubular cells, whereas Prx II, III and 
V were strongly expressed in distal tubules (Oberley, Verwiebe et al. 2001); or in lung, 
bronchial epithelium, alveolar epithelium and alveolar macrophages were showed 
different expression patterns of Prx subtypes (Kinnula, Lehtonen et al. 2002). An 
additional explanation is that Prx I may possibly not be the predominant subtype in 
cochlear hair cells. Western blotting analysis using a cell line of cochlear hair cell (UB/OC-
1) showed that Prx III was the most prominent subtype but not Prx I (Choi, Park et al. 
2008). Moreover, when Prx III siRNA was delivered to the inner ear, apoptosis of the 
cochlear OHCs significantly increased in response to noise trauma or aminoglycoside 
treatment (Chen, Zheng et al. 2013). 
Between cochlear OHCs and lateral wall, although there was no critical evidence of 
where cisplatin affects firstly, the fact that infusion of cisplatin induced the reduction of 
endocochlear potential (van Ruijven, de Groot et al. 2005) suggests that cochlear lateral 
wall might be the earlier target of cisplatin. Spiral ligament fibrocytes of the lateral wall 
have a vital function in recycling K+, providing K+ for the endolymph and thereby keeping 
the endolymph ionic concentration in balance (Zdebik, Wangemann et al. 2009). In 
addition, spiral ligament fibrocytes are closely involved with blood-cochlear barrier 
functioning in preventing ototoxic drugs (Juhn, Hunter et al. 2001), and the degradation 
of these fibrocytes showed a strong connection to hearing loss (Hequembourg and 
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Liberman 2001). In the present study, the vulnerability of the spiral ligament fibrocytes of 
Prx I-deficient mice indicates that Prx I may be involved in defense of the cochlea against 
cisplatin toxicity via fibrocyte protection. The expression of Prx I in this cell type assists 
the cleanup of reactive oxygen species and restrains the access of cisplatin to endolymph, 
which would destroy cochlear hair cells later. In vivo experiments also advocate this point 
since systemic administration of cisplatin at high dose showed little evidence of cochlear 
pathology while significant nephrotoxicity occurred; in contrast, applying cisplatin to 
mouse round windows or infusing it into middle ear space showed a considerable 
cochlear hair cell loss (He, Yin et al. 2009).  
 
3.5. Conclusion  
The present study provides evidence that mRNAs of all 6 Prx subtypes are expressed 
in the organ of Corti and showed their changings following cisplatin exposure. We hope 
this data could provide useful information for further inner ear research of Prx which are 
limited at the moment. Besides, Prx I showed its importance to spiral ligament fibrocytes 
of the lateral wall in cisplatin ototoxicity. 
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Chapter 4. Conclusions and perspectives 
4.1. Ceramide – 1 – phosphate  
Our results in chapter 2 provided further understandings of C1P and ceramide 
metabolism in cisplatin-induced cochlear hair cell death. Because C1P and ceramide 
could be interchangeable intracellularly, regulation of the enzymes involved in the 
metabolism of ceramides and C1P is vital for controlling the overall signal which is finally 
transmitted in cochlear hair cell. As well, because ceramide and C1P have opposing 
effects, these findings add a further understanding of the metabolic interrelationship of 
these metabolites particularly in cochlear hair cells, and suggest that alterations in the 
balance of the intracellular levels of ceramides and C1P can affect cochlear hair cell 
survival. Together with previous studies in our laboratory related to sphingolipid, we are 
gradually drawing a full picture of sphingolipid metabolites in ototoxicity which help us to 
partly understand toxic mechanisms of not only cisplatin but also gentamycin. With this 
understanding, we hope that it may help to find a cure or a prevention for patients who 
need to use platinum-based drugs. 
Up to now, it is not known whether C1P is present in plasma, or if it can be released 
into the extracellular environment upon cell activation. A general feature in cell signaling 
processes is that a signal, such as ceramide or C1P, is generated by the action of an 
enzyme or a group of enzymes acting in concert. The enzyme product will then activate 
specific downstream electors leading to a cascade of metabolic reactions that will end up 
stimulating or inhibiting a biological function. Therefore, further studies need to clarify 
these points. Although practical applications could not be reached at the moment, the 
development of inhibitors or activators of the enzymes that affect the intracellular 
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concentrations of C1P may be crucial for establishing therapeutic strategies; furthermore, 
administration of exogenous C1P, synthetic analogues of C1P, as well as C1P receptor 
agonists are other potential approaches. 
4.2. Peroxiredoxin I  
In chapter 3, we revealed that Prx I may play a protective role of cochlear lateral wall 
against cisplatin toxicity. This finding highlights a potential usefulness of Prx I as a 
protective factor that could ameliorate cisplatin-induced side effects on hearing function. 
The up-regulation of Prx I in cells and tissues under oxidative stress conditions is either 
enhancing the cellular defense capacity against oxidative damage or facilitating the 
recovery process from oxidative damage. Therefore, understanding mechanism of this 
up-regulation might have to shed a light on proper strategies to deal with oxidative stress 
of cisplatin. However, it is also worth to note that up-regulation of Prx I after oxidative 
damage, is likely to act in concert with other Prxs and the realm of other antioxidant 
enzymes and proteins, thus contributing in more or less specific ways to overall response 
to oxidative challenges.  
The contribution of oxidative stress in human disease states has long been recognized, 
and bolstering of antioxidative pathways may benefit to prevent chronic diseases, such 
as cardiovascular diseases, cancer, diabetes mellitus, and so on. However, we do have 
a lot of questions remaining unanswered in this field. For example, what directly or 
indirectly affects Prx synthesis, release, and breakdown is still not well understood. What 
pharmacologic or non-pharmacologic treatment interventions can modulate Prx levels are 
also unclear currently. However, what we could do is to find the association between their 
levels and severity of a related disease as the first step in this long-term plan; therefore, 
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we could determine whether it is a possible biomarker for diagnosis or prognosis a 
disease.  
4.3. Concluding remarks 
Although many studies concentrate on cisplatin ototoxicity, there are a lot of 
unanswered questions in this filed, and the best way to find a suitable toxic treatment is 
to fully understand its mechanism. In our study, we suggested that C1P, ceramide kinase 
or Prx I could be a possible target in dealing with cisplatin ototoxicity. An effective method 
to reduce cisplatin ototoxicity is still waiting ahead, and we hope our findings will build a 
small step to archive it soon. 
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